Cargando…

Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy

BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgado, Maria, Rabi, S Alireza, O'Connell, Karen A, Buckheit III, Robert W, Bailey, Justin R, Chaudhry, Amina A, Breaud, Autumn R, Marzinke, Mark A, Clarke, William, Margolick, Joseph B, Siliciano, Robert F, Blankson, Joel N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293762/
https://www.ncbi.nlm.nih.gov/pubmed/22141397
http://dx.doi.org/10.1186/1742-4690-8-97
_version_ 1782225417010151424
author Salgado, Maria
Rabi, S Alireza
O'Connell, Karen A
Buckheit III, Robert W
Bailey, Justin R
Chaudhry, Amina A
Breaud, Autumn R
Marzinke, Mark A
Clarke, William
Margolick, Joseph B
Siliciano, Robert F
Blankson, Joel N
author_facet Salgado, Maria
Rabi, S Alireza
O'Connell, Karen A
Buckheit III, Robert W
Bailey, Justin R
Chaudhry, Amina A
Breaud, Autumn R
Marzinke, Mark A
Clarke, William
Margolick, Joseph B
Siliciano, Robert F
Blankson, Joel N
author_sort Salgado, Maria
collection PubMed
description BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4(+ )T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4(+ )T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8(+ )T cells do not have potent HIV suppressive activity. CONCLUSION: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors.
format Online
Article
Text
id pubmed-3293762
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32937622012-03-06 Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy Salgado, Maria Rabi, S Alireza O'Connell, Karen A Buckheit III, Robert W Bailey, Justin R Chaudhry, Amina A Breaud, Autumn R Marzinke, Mark A Clarke, William Margolick, Joseph B Siliciano, Robert F Blankson, Joel N Retrovirology Research BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4(+ )T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4(+ )T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8(+ )T cells do not have potent HIV suppressive activity. CONCLUSION: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors. BioMed Central 2011-12-05 /pmc/articles/PMC3293762/ /pubmed/22141397 http://dx.doi.org/10.1186/1742-4690-8-97 Text en Copyright ©2011 Salgado et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Salgado, Maria
Rabi, S Alireza
O'Connell, Karen A
Buckheit III, Robert W
Bailey, Justin R
Chaudhry, Amina A
Breaud, Autumn R
Marzinke, Mark A
Clarke, William
Margolick, Joseph B
Siliciano, Robert F
Blankson, Joel N
Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title_full Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title_fullStr Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title_full_unstemmed Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title_short Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
title_sort prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293762/
https://www.ncbi.nlm.nih.gov/pubmed/22141397
http://dx.doi.org/10.1186/1742-4690-8-97
work_keys_str_mv AT salgadomaria prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT rabisalireza prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT oconnellkarena prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT buckheitiiirobertw prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT baileyjustinr prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT chaudhryaminaa prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT breaudautumnr prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT marzinkemarka prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT clarkewilliam prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT margolickjosephb prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT silicianorobertf prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy
AT blanksonjoeln prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy